Type of Spiritual Experience
A description of the experience
Trospium chloride (INN) is a muscarinic antagonist urinary antispasmodic. It and is sold under the brand name Sanctura in the US, Tropez OD in India, Trosec in Canada, Regurin and Flotros in the United Kingdom, Spasmex in Germany, Russia, Turkey, Argentina, Chile and Israel and Spasmolyt manufactured by Madaus in Germany and marketed in Germany, Austria, Bulgaria, Denmark, Finland, Luxembourg, Poland, Thailand, Malaysia and Middle-East countries. It is available in Egypt under the brand name Spasmex in Europe under the trade name Inkontan and it is available as 15 mg and 30 mg film-coated tablets.
Trospium chloride is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. Trospium chloride is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.
Risk of urinary retention
Trospium chloride should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
Decreased gastrointestinal motility
Trospium chloride should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention . Trospium chloride, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis.
In patients being treated for narrow-angle glaucoma, trospium chloride should only be used if the potential benefits outweigh the risks and in that circumstance only with careful monitoring.
Dose modification is recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min). In such patients, trospium chloride should be administered as 20 mg once a day at bedtime .
Caution should be used when administering trospium chloride in patients with moderate or severe hepatic impairment .
On Dec, 21, 2016 796 people reported to have side effects when taking Trospium Chloride. Among them, 6 people (0.75%) have Hallucination
On Feb, 13, 2016: 502 people reported to have side effects when taking Trospium chloride. Among them, 5 people (1.00%) have Death.